The onset of
            <i>de novo</i>
            autoantibodies in healthcare workers after mRNA based anti-SARS-CoV-2 vaccines: a single centre prospective follow-up study

Sacchi, M.C; Pelazza, C.; Bertolotti, M.; Agatea, L.; De Gaspari, P.; Tamiazzo, S.; Ielo, D.; Stobbione, P.; Grappiolo, M.; Bolgeo, T.; Novel, P.; Ciriello, M.M; Maconi, A.

doi:10.1080/08916934.2023.2229072

Cited by 13 publications

(8 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prior studies have identified low incidences of de novo serum autoantibody formation after 3-dose SARS-CoV-2 vaccination ( 19 – 21 ). A subset of hospitalized COVID patients develop new autoantibodies after SARS-CoV-2 infection ( 22 ).…”

Section: Resultsmentioning

confidence: 99%

“…Neither induction of de novo autoantibodies nor major adverse reactions were observed in patients with SLE during the 42-day study. Prior studies have identified low incidences of de novo serum autoantibody formation after 3-dose SARS-CoV-2 vaccination (19)(20)(21). A subset of hospitalized COVID patients develop new autoantibodies after SARS-CoV-2 infection (22).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus

Sarin,

Zheng,

Chaichian

et al. 2024

JCI Insight

View full text Add to dashboard Cite

Understanding the immune responses to SARS-CoV-2 vaccination is critical to optimizing vaccination strategies for individuals with autoimmune diseases, such as systemic lupus erythematosus (SLE). Here, we comprehensively analyzed innate and adaptive immune responses in 19 patients with SLE receiving a complete 2-dose Pfizer-BioNTech mRNA vaccine (BNT162b2) regimen compared with a control cohort of 56 healthy control (HC) volunteers. Patients with SLE exhibited impaired neutralizing antibody production and antigen-specific CD4 + and CD8 + T cell responses relative to HC. Interestingly, antibody responses were only altered in patients with SLE treated with immunosuppressive therapies, whereas impairment of antigen-specific CD4 + and CD8 + T cell numbers was independent of medication. Patients with SLE also displayed reduced levels of circulating CXC motif chemokine ligands, CXCL9, CXCL10, CXCL11, and IFN-γ after secondary vaccination as well as downregulation of gene expression pathways indicative of compromised innate immune responses. Single-cell RNA-Seq analysis reveals that patients with SLE showed reduced levels of a vaccine-inducible monocyte population characterized by overexpression of IFN-response transcription factors. Thus, although 2 doses of BNT162b2 induced relatively robust immune responses in patients with SLE, our data demonstrate impairment of both innate and adaptive immune responses relative to HC, highlighting a need for population-specific vaccination studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus

Sarin,

Zheng,

Chaichian

et al. 2024

JCI Insight

View full text Add to dashboard Cite

show abstract

“…Гиперпродукция характерных для САРЗ антинуклеарных (ядерных) антител (АНА) ассоциируется с тяжёлым течением COVID-19, активностью воспаления, развитием «длительного» COVID-19 [117,[154][155][156][157][158][159][160][161][162][163]. S.E.…”

Section: антинуклеарные антителаunclassified

“…Увеличение титров АНА (гомогенное свечение по данным НИФ) выявлено после вакцинации против SARS-CoV-2, однако динамика уровня потенциально патогенных аутоантител (АНЦА, аФЛ и др.) отсутствовала [162]. По данным W. Zhang и соавт.…”

Section: антинуклеарные антителаunclassified

Coronavirus disease 2019 (COVID-19) pandemic and autoimmune rheumatic diseases: Outcomes and prospects

Nasonov

2024

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

The pandemic of coronavirus disease 2019 (COVID-19), etiologically related to the SARS-CoV-2 virus (severe acute respiratory syndrome coronavirus-2), has drawn attention to new clinical and fundamental problems in the immunopathology of human diseases associated with virus-induced autoimmunity and autoinflammation. The provision that “the experience gained in rheumatology in the process of studying the pathogenetic mechanisms and pharmacotherapy of immunoinflammatory rheumatic diseases as the most common and severe forms of autoimmune and autoinflammatory pathology in humans will be in demand for deciphering the nature of the pathological processes underlying COVID-19 and developing approaches to effective pharmacotherapy” was confirmed in numerous studies conducted over the next 3 years in the midst of the COVID-19 pandemic. The main focus will be on a critical analysis of data regarding the role of autoimmune inflammation, which forms the basis of the pathogenesis of immune-mediated rheumatic diseases in the context of the immunopathology of COVID-19.

show abstract

“…Because of their high prevalence and increased comorbidity risk, autoantibodies other than neural autoantibodies are relevant, such as antinuclear autoantibodies. A recent study [ 46 ] showed that vaccination in healthcare workers also led to a significant increase in de novo autoantibodies against nuclear antigens. Such study evidence makes it clear that an interdisciplinary approach is best, and that in patients presenting neuropsychiatric or purely psychiatric symptoms and suspected PCS, it is advisable to assess both neural autoantibodies and antinuclear antibodies.…”

Section: Therapeutic and Biomarker-supported Approachmentioning

confidence: 99%

Psychiatric Symptoms in Acute and Persisting Forms of COVID-19 Associated with Neural Autoantibodies

Hansen

2023

Antibodies

View full text Add to dashboard Cite

(1) Background: In this narrative review, we focus on neural autoantibodies in patients with coronavirus disease 2019 (COVID-19) as a consequence of severe acute respiratory syndrome coronavirus type 2 infection and persisting symptoms of post-COVID-19 syndrome with a psychiatric presentation. (2) Methods: Our methods include using the PubMed database to search for appropriate articles. (3) Results: We first describe the phenomenon of the psychiatric manifestation of COVID-19 in acute and persistent forms, associated with neural autoantibodies, often attributable to encephalopathy or encephalitis. We discuss the spectrum of neural autoantibodies in neuropsychiatric patients affected by COVID-19 and post-COVID-19 syndrome. Evidence from our research suggests that it is highly likely that neural autoantibody production is facilitated by SARS-CoV-2 infection, and that more neuropsychiatric patients than control subjects will present neural autoantibodies. (4) Conclusions: These observations support the hypothesis that acute and persisting forms of COVID-19 promote autoimmune diseases. Our patients therefore require comprehensive evaluation to avoid overlooking such autoantibody-associated psychiatric disorders associated with COVID-19.

show abstract

The onset of de novo autoantibodies in healthcare workers after mRNA based anti-SARS-CoV-2 vaccines: a single centre prospective follow-up study

Cited by 13 publications

References 51 publications

Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus

Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus

Coronavirus disease 2019 (COVID-19) pandemic and autoimmune rheumatic diseases: Outcomes and prospects

Psychiatric Symptoms in Acute and Persisting Forms of COVID-19 Associated with Neural Autoantibodies

Contact Info

Product

Resources

About